Oncopeptides
Oncopeptides AB is a Swedish biopharmaceutical company dedicated to the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases. The company utilizes its proprietary Peptide-Drug Conjugate (PDC) platform to develop novel drugs that concentrate cytotoxic agents directly within cancer cells, primarily focusing on its flagship product Pepaxti (melflufen) for the treatment of relapsed and refractory multiple myeloma. Its core operations encompass preclinical oncology research, clinical trial advancement, and European commercialization efforts. Revenue is derived primarily from the commercial sales of Pepaxti in approved European markets, alongside strategic licensing partnerships. Oncopeptides holds a specialized position in precision oncology and peptide-based cancer treatments. The company is headquartered in Stockholm, Sweden, and its shares trade on Nasdaq Stockholm.
3 of the funds FundTelligence covers report a position in Oncopeptides.
- Legal name
- Oncopeptides AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 3
Funds holding Oncopeptides
- Storebrand Sverige Småbolag Plus — Storebrand · 0.04 % (full portfolio disclosed, October 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)